



902.1005US

**UNITED STATES PATENT AND TRADEMARK OFFICE**

Examiner: Blessing M. Fubara      Art Unit: 1618  
Re:    Application of:      MANGENA, Murty  
Serial No.:      10/646,990  
Filed:      August 27, 2003  
For:      BUPRENORPHINE MICROSPHERES

**INFORMATION DISCLOSURE**  
**STATEMENT UNDER 37 C.F.R. § 1.56**

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

04/18/2007 WASFAM 00000016 10646998  
April 19, 2007  
02 FC:1806      188.08 OP

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (2 sheets) for consideration by the Examiner in connection with the examination of the above-identified patent application.


Pursuant to 37 C.F.R. § 1.98 (a), the foreign patent references listed on the attached form PTO-1449 are enclosed as AD and AE. An English language translation is provided for reference AD. Reference AF is submitted as an English language counterpart is AE. If it is determined that any of the listed references are not presently enclosed, the Examiner is requested to contact the undersigned so that a copy can be forwarded.

It is respectfully requested that the references cited in the accompanying Form PTO-1449 (2 sheets) be considered and made of record.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97 C). A check is enclosed to cover the requisite \$180.00 fee. In the event any additional fee is due or any overpayment made in connection with the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge said deficiency or credit overpayment to our Deposit Account No. 50-0552.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By



Clifford M. Davidson  
Reg. No. 32,728

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
(212) 736-1940

APR 17 2007

Sheet 1 of 2

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
902.1005USSERIAL NO.:  
10/649,990

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):  
Murty MANGENAFILING DATE:  
August 27, 2003GROUP:  
1818

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AD	4 5 6 8 2 4		FR			X	
AE	1 4 7 8 8 9 4		FR				X
AF	1 1 2 3 4 4 5		GB				X

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AG	Brewster, D.; Humphrey, M.J.; Mcleavy, M.A. <i>J. Pharm. Pharmacol.</i> , 33,500-6 (1981)
AH	Ravis, W.R.; Koster, A.S. <i>In Progress in Pharmacology and Clinical Pharmacology</i> , Eds.: Gustav Fischer Verlag, New York, 7,275-287 (1989)
AI	Bullingham, R.E.; McQuay, H.J.; Deyer, D.; Allen, M.C.; Moore, R.A. <i>Br. J. Clin. Pharmacol.</i> , 12, 117-22 (1981)
AJ	Foley, K.M.; Inturissi, C.E. <i>In Advances in Pain Research and Therapy</i> , Ed.: Raven, New York, 8,117-127-1986
AK	Eriksen, J.; Jensen, N.H.; Kamp-Jensen, M.; Bjarno, H.; Früs, P.; Brewster, D., <i>J Pharm. Pharmacol.</i> , 41, 803-805 (1989)
AL	Cha, Y.; Pitt C. G. <i>J. Cont. Rel.</i> , 7, 68-78 (1988)
AM	Cohen, S.; Yoshioka, T.; Lucarelli, M.; Hwary, L.; Langer, R. <i>Pharm. Res.</i> , 8,713-20 (1991)
AN	Schwoppe, A.D.; Wise, D.L.; Howes, J.F. <i>Life Sci.</i> , 17, 1877-85 (1975)
AO	Ogawa, Y.; Yamamoto, M.; Okada, H.; Shimamoto, T. <i>Chem. Pharm. Bull.</i> , 36, 2576-81 (1988)
AP	Ogawa, Y.; Yamamoto, M.; Okada, H.; Yashiki, T.; Shimamoto, T. <i>Chem. Pharm. Bull.</i> , 36, 1095-1103 (1988)
AQ	Mason, N.; Thies, C.; Cicero, T. <i>J. Pharm. Sci.</i> , 65, 847-50 (1976)
AR	Klement, W.; Kindgen-Milles, O. <i>Pharm. Res.</i> , 9, 1233-34 (1992)
AS	Thies, C.; Bissery, M.; <i>Biodegradable Microspheres for Parenteral Administration</i> ; in Lim F (ed): Biomedical applications of microencapsulation, Boca Raton, Florida, CRC Press, Inc. 1984, pp 53-74

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 902.1005US

SERIAL NO.: 10/849,990

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Murty MANGENA

FILING DATE: August 27, 2003

GROUP: 1618

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BE							
	BF							
	BG							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BH	Radwan, M. <i>Drug. Dev. Ind. Pharm.</i> , 20, 2753-62 (1994)
BI	Anderson, F.D.; Archer, D.F.; Harman, S.M. <i>Pharm. Res.</i> , 10, 369-380 (1993)
BJ	Johnston, T.P.; Miller, S.C. <i>J. Parent Sci. Technol.</i> , 39, 83-88 (1985)
BK	Shintani, S.; Yamazaki, M.; Nakamura, M. <i>Toxicol. Appl. Pharmacol.</i> , 11, 283-301 (1987)
BL	Katakam, M. Ravis, W.R.; Bonga, A. <i>J. J. Cont. Rel.</i> (in press)
BM	Proost, J.; H. <i>J. Pharm. Sci.</i> , 74, 793-794 (1985)
BN	Ravis, W.R.; Ganjam, V.K.; Comerci, C. <i>Biopharm. Drug. Disp.</i> , 7, 407 (1986)
BO	Cutler, D.; J. <i>J. Pharmacol. Biopharm.</i> , 6, 227-241 (1977)
BP	Kulkarni, R.K.; Pani, K.; Neuman, C.; Leonard, F. <i>Arch. Surg.</i> , 93, 839-43 (1966)
BQ	Ravis, W.R.; <i>Data Interpretation and Analysis in Percutaneous Absorption Studies</i> , Eds. W.G. Reitenrath and B.W. Kampainen For Skin Absorption, CRC Publications 147-163 (1980).
BR	Vissscher, G.E.; Robison, R.L.; Maudling, H.V.; Fong J. W.; Pearson, J.E.; Argentieri, G.J. <i>J. Biomed. Mater. Res.</i> , 19, 349-65 (1985)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.